To study leukapheresis and tisagenlecleucel manufacturing outcomes in pts <3 years old with r/r B-ALL in the US commercial setting since regulatory approval
Latest Information Update: 31 Jan 2022
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 31 Jan 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition